Fig. 5: Duration of treatment and molecular response for patients achieving CR or sCR.
From: Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
MRD status was assessed by next-generation sequencing at a sensitivity of 1 × 10−5 in accordance with IMWG criteria. Evaluable patients had a dominant VDJ or VJ sequence at baseline and confirmed response of CR or better. Black asterisk indicates ‘not evaluable’. u, unconfirmed.
